Corporate Structure, Indirect Bankruptcy Costs, and the Advantage of De Novo Firms: The Case of Gene Therapy Research

References

• Abernathy WJ, Utterback JM (1978) Patterns of industrial innovation. Tech. Rev. 80(7):40–47.Google Scholar
• Adner R, Levinthal DA (2004a) What is not a real option: Considering boundaries for the application of real options to business strategy. Acad. Management Rev. 29(1):74–85.Crossref, Google Scholar
• Adner R, Levinthal DA (2004b) Real options and real tradeoffs. Acad. Management Rev. 29(1):120–126.Crossref, Google Scholar
• American Cancer Society (2000) Cancer facts and figures. Report, American Cancer Society, Washington, DC. http://www.cancer.org/downloads/STT/F&F00.pdf. [Last accessed March 10, 2008 (site discontinued).]Google Scholar
• American Cancer Society (2004) Cancer facts and figures. Report, American Cancer Society, Washington, DC. http://www.cancer.org/downloads/STT/CAFF_finalPWSecured.pdf. [Last accessed March 25, 2009 (site discontinued).]Google Scholar
• Arora A, Fosfuri A, Gambardella A (2004) Markets for Technology: The Economics of Innovation and Corporate Strategy (MIT Press, Cambridge, MA).Google Scholar
• Bechky BA (2006) Gaffers, gofers, and grips: Role-based coordination in temporary organizations. Organ. Sci. 17(1):3–21.Link, Google Scholar
• Benner MJ (2010) Securities analysts and incumbent response. Organ. Sci. 21(1):42–62.Link, Google Scholar
• Benner MJ, Tripsas M (2012) The influence of prior industry affiliation on framing in nascent industries: The evolution of digital cameras. Strategic Management J. 33(3):277–302.Crossref, Google Scholar
• Brealey RA, Myers SC, Allen F (2010) Principles of Corporate Finance, 10th ed. (McGraw-Hill, New York).Google Scholar
• Capdeville R, Buchdunger E, Zimmermann J, Matter A (2002) Glivec (STI571, imanitib), a rationally developed, targeted anticancer drug. Nature Rev. Drug Discovery 1(7):493–502.Crossref, Google Scholar
• Carroll GR, Bigelow LS, Seidel M-DL, Tsai LB (1996) The fates of de novo and de alio producers in the American automobile industry 1885–1981. Strategic Management J. 17(S1):117–137.Crossref, Google Scholar
• Chabner BA, Roberts TG Jr (2005) Chemotherapy and the war on cancer. Nature Rev. Cancer 5(1):65–72.Crossref, Google Scholar
• Christensen C, Bower J (1996) Customer power, strategic investment, and the failure of leading firms. Strategic Management J. 17(3):197–218.Crossref, Google Scholar
• Clark KB (1985) The interaction of design hierarchies and market concepts in technological innovation. Res. Policy 14(5):235–251.Crossref, Google Scholar
• Cohen LE (2012) Assembling jobs: A model of how tasks are bundled into and across jobs. Organ. Sci. 24(2):432–454.Link, Google Scholar
• Cohen WM, Levinthal DA (1990) Absorptive capacity—A new perspective on learning and innovation. Admin. Sci. Quart. 35(1): 128–152.Crossref, Google Scholar
• Cotrim AP, Baum BJ (2008) Gene therapy: Some history, applications, problems and prospects. Toxicol. Pathol. 36(1):97–103.Crossref, Google Scholar
• Datamonitor (2011) MolMed to develop production process for ADA-SCID gene therapy. Press release (August 10), MolMed, Milan, Italy.Google Scholar
• Dateline NBC (2012) Episode 1927 (Profile: The Hansen files—Investigation into how drugs get approved). First broadcast March 4 by NBC News. Transcript retrieved from Factiva, September 11, 2012.Google Scholar
• Edelstein ML, Abedi MR, Wixon J (2007) Gene therapy clinical trials worldwide to 2007—An update. J. Gene Medicine 9(10):833–842.Crossref, Google Scholar
• Edelstein ML, Abedi MR, Wixon J, Edelstein RM (2004) Gene therapy clinical trials worldwide 1989–2004—An overview. J. Gene Medicine 6(6):597–602.Crossref, Google Scholar
• Feldman M (2003) The locational dynamics of the US biotech industry: Knowledge externalities and the anchor hypothesis. Indust. Innovation 10(3):311–329.Crossref, Google Scholar
• Fernández-Mateo I (2009) Cumulative gender disadvantage in contract employment. Amer. J. Sociol. 114(4):871–923.Crossref, Google Scholar
• Ferrera N, Hillan KJ, Gerber H, Novotny W (2004) Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nature Rev. Drug Discovery 3(5):391–400.Crossref, Google Scholar
• Financial Times (1995) Weekend money (company in the news)—Boot’s 600 M poser. Financial Times (June 3). Retrieved from Factiva, August 29, 2012.Google Scholar
• Friedmann T (1992) A brief history of gene therapy. Nature Genetics 2(2):93–98.Crossref, Google Scholar
• Gans JS, Stern S (2003) The product market and the market for “ideas”: Commercialization strategies for technology entrepreneurs. Res. Policy 32(2):333–350.Crossref, Google Scholar
• Glaser BG, Strauss AL (1967) The Discovery of Grounded Theory (Aldine Publishing, Hawthorne, NY).Google Scholar
• Guedj I, Scharfstein D (2004) Organizational scope and investment: Evidence from the drug development strategies and performance of biopharmaceutical firms. NBER Working Paper 10933, National Bureau of Economic Research, Cambridge, MA.Google Scholar
• Henderson RM (1993) Underinvestment and incompetence as responses to radical innovation—Evidence from the photolithographic alignment equipment industry. RAND J. Econom. 24: 248–270.Crossref, Google Scholar
• Holmstrom B (1989) Agency costs and innovation. J. Econom. Behav. Organ. 12(3):305–327.Crossref, Google Scholar
• Huising R (2012) Becoming a workplace activist. Working paper, McGill University, Montreal.Google Scholar
• Jia H (2006) Controversial Chinese gene-therapy drug entering unfamiliar territory. Nature Rev. Drug Discovery 5(4):269–270.Crossref, Google Scholar
• Jia H (2007) Gene dreams troubled by market realities. Chemistry World (August 31) http://www.rsc.org/chemistryworld/Issues/2007/September/GeneDreamsTroubledMarketRealities.asp.Google Scholar
• Kaplan S (2008) Cognition, capabilities, and incentives: Assessing firm response to the fiber-optic revolution. Acad. Management J. 51(4):672–695.Crossref, Google Scholar
• Kaplan S, Murray F (2010) Entrepreneurship and the construction of value in biotechnology. Phillips N, Griffiths D, Sewell G, eds. Technology and Organization: Essays in Honour of Joan Woodward, Research in the Sociology of Organizations, Vol. 29 (Emerald Group Publishing, Bingley, UK), 107–147.Crossref, Google Scholar
• Kaplan S, Tripsas M (2008) Thinking about technology: Applying a cognitive lens to technical change. Res. Policy 37(5):790–805.Crossref, Google Scholar
• Kaplan S, Murray F, Henderson RM (2003) Discontinuities and senior management: Assessing the role of recognition in pharmaceutical firm response to biotechnology. Indust. Corporate Change 12(4):203–233.Crossref, Google Scholar
• Kellogg KC (2009) Operating room: Relational spaces and microinstitutional change in surgery. Amer. J. Sociol. 115(3):657–711.Crossref, Google Scholar
• Kimmelman J (2009) Ethics of cancer gene transfer clinical research. Walther W, Stein US, eds. Methods in Molecular Biology, Gene Therapy of Cancer, Vol. 542 (Humana Press, Totowa, NJ), 423–445.Crossref, Google Scholar
• Klepper S, Thompson P (2006) Submarkets and the evolution of market structure. RAND J. Econom. 37(4):861–886.Crossref, Google Scholar
• Kohn DB, Candotti F (2009) Gene therapy fulfilling its promise. New England J. Medicine 360(5):518–521.Crossref, Google Scholar
• Loftus P (2007) Tales of the tape: Investors mull safety of Arena’s diet pill. Dow Jones News (June 12). Retreived from Factiva, August 29, 2012.Google Scholar
• McGrath RG (1997) A real options logic for initiating technology positioning investments. Acad. Management Rev. 22(4):974–996.Crossref, Google Scholar
• McGrath RG, Nerkar A (2004) Real options reasoning and a new look at the R&D investment strategies of pharmaceutical firms. Strategic Management J. 25(1):1–21.Crossref, Google Scholar
• McGrath RG, Ferrier WJ, Mendelow AL (2004) Real options as engines of choice and heterogeneity. Acad. Management Rev. 29(1):86–101.Crossref, Google Scholar
• Merck & Co. (2004) Merck announces voluntary worldwide withdrawal of Vioxx™. Press release (September 30), Merck & Co., North Wales, PA. http://www.pbm.va.gov/vacenterformedicationsafety/vioxx/DearHealthcareProfessional.pdf.Google Scholar
• Nagata S, Taira H, Hall A, Johnsrud L, Streuli M, Ecsödi J, Boll W, Cantell K, Weissmann C (1980) Synthesis in E. coli of a polypeptide with human leukocyte interferon activity. Nature 284(5754):316–320.Crossref, Google Scholar
• Nature (2007) Nature milestones in DNA technologies: PDF of all milestones. Nature (October, supplement):S5–S20.Google Scholar
• Panem S (1984) The Interferon Crusade (Brookings Institution, Washington, DC).Google Scholar
• Parsons SJ, Parsons JT (1987) Monoclonal antibodies to oncogene products. Schook LB, ed. Monoclonal Antibody Production Techniques and Applications (Marcel Dekker, New York), 207–228.Google Scholar
• Rang HP (2006) The drug discovery process: General principles and some case histories. Rang HP, ed. Drug Discovery and Development: Technology in Transition (Churchill Livingstone, London), 43–56.Google Scholar
• Reuters (2006) Merck sees slightly higher 2007 earnings. New York Times (December 7) http://www.nytimes.com/2006/12/07/business/07drug.html.Google Scholar
• Roberts TG Jr, Goulat BH, Squitieri L, Stallings SC, Halpern EF, Chabner BA, Gazelle GS, Finkelstein SN, Clark JW (2004) Trends in the risks and benefits to patients with cancer participating in phase 1 clinical trials. J. Amer. Medical Assoc. 292(17):2130–2140.Crossref, Google Scholar
• Ryser S, Weber M (1990) Genetic Engineering—A Chronology, 2nd rev. ed. (Editiones Roche, Basel, Switzerland).Google Scholar
• Sleigh S, Barton CL (2011) Risk evaluation and mitigation strategies (REMS): Detecting risk pre-market, managing risk post-approval, and the role of US and EU regulators. Report, Business Insights, London. http://www.popewoodhead.com/downloads/SCRIP_REMS_Aug11.pdf.Google Scholar
• Sosa ML (2011) From old competence destruction to new competence access: Evidence from the comparison of two discontinuities in anticancer drug discovery. Organ. Sci. 22(6):1500–1516.Link, Google Scholar
• Stuart TE, Hoang H, Hybels RC (1999) Interorganizational endorsements and the performance of entrepreneurial ventures. Admin. Sci. Quart. 44(2):315–349.Crossref, Google Scholar
• Sutton J (1998) Technology and Market Structure: Theory and Structure (MIT Press, Cambridge, MA).Google Scholar
• Teece DJ, Pisano G, Schuen A (1997) Dynamic capabilities and strategic management. Strategic Management J. 18(7):509–533.Crossref, Google Scholar
• Thompson L (2000) Human gene therapy: Harsh lessons, high hopes. FDA Consumer 34(5):19–24.Google Scholar
• Tilton JE (1971) International Diffusion of Technology: The Case of Semiconductors (Brookings Institution, Washington, DC).Google Scholar
• Tripsas M (1997) Unraveling the process of creative destruction: Complementary assets and incumbent survival in the typesetter industry. Strategic Management J. 18(Summer special issue): 119–142.Crossref, Google Scholar
• Tripsas M (2008) Customer preference discontinuities: A trigger for radical technological change. Managerial Decision Econom. 29:79–97.Crossref, Google Scholar
• Tripsas M (2009) Technology, identity, and inertia through the lens of “The Digital Photography Company”. Organ. Sci. 20(2):441–460.Link, Google Scholar
• Tripsas M, Gavetti G (2000) Capabilities, cognition, and inertia: Evidence from digital imaging. Strategic Management J. 21(10–11):1147–1161.Crossref, Google Scholar
• Tushman M, Anderson P (1986) Technological discontinuities and organizational environments. Admin. Sci. Quart. 31(3):439–465.Crossref, Google Scholar
• Tyle P, Ram BP (1990) Monoclonal antibodies, immunoconjugates and liposomes as targeted therapeutic systems. Tyle P, Ram BP, eds. Targeted Therapeutic Systems (CDC Press, Boca Raton, FL), 3–24.Google Scholar
• Vassolo RS, Anand J, Folta TB (2004) Non-additivity in portfolios of exploration activities. Strategic Management J. 25(11):1045–1061.Crossref, Google Scholar
• Ziedonis AA (2007) Real options in technology licensing. Management Sci. 53(10):1618–1633.Link, Google Scholar